Regranex Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The regranex market research report is one of a series of new reports that provides regranex market statistics, including the regranex industry global market size, regional shares, competitors with the regranex market share, detailed regranex market segments, market trends, and opportunities, and any further data you may need to thrive in the regranex industry. This regranex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the rising incidence of chronic wounds, rising prevalence of diabetes, increasing adoption of stem cell technology, growing number of wound care centers, and rising prevalence of musculoskeletal disorders. Major trends in the forecast period include advanced wound care solutions, technological integration and digital health solutions, innovative treatment options, technological advancements in wound monitoring, and the integration of telemedicine for wound care.

The increasing prevalence of diabetes is expected to drive the growth of the regranex market in the coming years. Diabetes is a group of diseases that impact how the body processes blood sugar, with Type 1 diabetes, where the body doesn’t produce insulin, and Type 2 diabetes, where the body becomes resistant to insulin or produces insufficient amounts. The rise in diabetes cases is attributed to factors such as unhealthy diets, sedentary lifestyles, obesity, genetic predisposition, aging populations, and urbanization. Regranex helps manage diabetes-related complications by promoting the healing of diabetic foot ulcers, preventing severe outcomes such as amputations. For example, a report from the Office for Health Improvement and Disparities in March 2024 showed that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. Additionally, the percentage of people achieving target HbA1c levels increased to 37.9%, the highest level recorded by the National Diabetes Audit. Therefore, the rising prevalence of diabetes is contributing to the growth of the regranex market.

The growing incidence of chronic wounds is also expected to drive the expansion of the regranex market. Chronic wounds are long-lasting injuries that do not heal within the typical 4-6 week timeframe, often resulting from conditions such as diabetes, venous insufficiency, or prolonged pressure. The increase in chronic wounds is linked to factors such as an aging population, the growing prevalence of diabetes and obesity, vascular diseases, and lifestyle-related issues that impair the body’s natural healing processes. Regranex (becaplermin) helps reduce the occurrence of chronic wounds by promoting the healing of diabetic foot ulcers. Its active ingredient, recombinant human platelet-derived growth factor (rhPDGF-BB), stimulates cell proliferation and tissue regeneration at the wound site. For instance, a report from OSF HealthCare in July 2023 highlighted that approximately 6.7 million people in the U.S. live with chronic wounds, with this number expected to grow by more than 2% annually over the next decade. As a result, the rising incidence of chronic wounds is supporting the growth of the regranex market.

The expansion of healthcare infrastructure is also expected to boost the growth of the regranex market. Healthcare infrastructure refers to the physical and organizational systems, including healthcare facilities, equipment, health information technology, and utilities, that enable effective delivery of medical services. The growth in healthcare infrastructure is driven by factors such as increasing healthcare demand, technological advancements, investments from the public and private sectors, urbanization, healthcare policy reforms, and rising healthcare expenditures. Regranex contributes to healthcare infrastructure by promoting faster wound healing, reducing hospitalizations, and improving patient outcomes, which in turn enhances cost efficiency. For example, a report by the American Health Care Association in May 2023 revealed that the United States had 6,129 hospitals, a 0.591% increase from the previous year, when there were 6,093 hospitals. Therefore, the growth in healthcare infrastructure is positively impacting the regranex market.

The key company operating in the regranex market is Smith And Nephew plc

North America was the largest region in the regranex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in regranex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the regranex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Regranex is a topical medication that contains becaplermin, a recombinant form of platelet-derived growth factor (PDGF). It is used to promote the healing of diabetic foot ulcers by stimulating tissue regeneration and the growth of blood vessels.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for regranex include diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Diabetic foot ulcers (DFUs) are sores that develop on the feet due to nerve damage and poor circulation in individuals with diabetes, which can lead to infections and potentially amputations if left untreated. Regranex is available in several formulations, including topical gel, ointment, and combination therapies. It is distributed through various channels such as direct sales, wholesalers, retail pharmacies, and online pharmacies, serving diverse end users, including pediatric, adult, and geriatric populations.

The regranex market consists of sales of products including dermagraft, oasis wound matrix, strataGraft, apligraf, and acticoat. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.